

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

Table 01: Study population and enrolment information
Full Analysis Dataset : NORWAY

Number of prospective patients (C1+C2+C3+C4+C5)	272
Number of enrolling sites	12
Number of enrolling countries	1
Enrolment period	21JAN2011 - 22JUL2016
Duration of enrolment (months)	66.0

**Table 02: Patients by region, country, and cohort
Full Analysis Dataset : NORWAY**

Region	Country	Cohort 1 Retrospective patients (N=75)	Cohort 1 Prospective patients (N=48)	Cohort 2 (N=69)	Cohort 3 (N=95)	Cohort 4 (N=31)	Cohort 5 (N=29)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Europe	Norway	75	48	69	95	31	29	272	243

**Table 03 : Demographic Characteristics
Full Analysis Dataset : NORWAY**

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Sex, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	Male	51 (68.0)	27 (56.3)	42 (60.9)	60 (63.2)	20 (64.5)	18 (62.1)	167 (61.4)	149 (61.3)
	Female	24 (32.0)	21 (43.8)	27 (39.1)	35 (36.8)	11 (35.5)	11 (37.9)	105 (38.6)	94 (38.7)
Age at Diagnosis (Years)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	Mean (SD)	67.9 (9.8)	69.6 (10.7)	69.6 (9.9)	69.4 (8.9)	68.7 (10.7)	71.0 (11.7)	69.6 (10.0)	69.4 (9.7)
	Median (IQR)	67.0 (62.0 to 74.0)	69.5 (65.5 to 78.0)	70.0 (64.0 to 77.0)	69.0 (64.0 to 76.0)	70.0 (61.0 to 77.0)	72.0 (64.0 to 81.0)	70.0 (64.0 to 77.0)	70.0 (64.0 to 77.0)
	Min to Max	43 to 91	36 to 88	39 to 91	44 to 91	38 to 87	35 to 86	35 to 91	36 to 91
Age Group, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	<65	31 (41.3)	11 (22.9)	18 (26.1)	27 (28.4)	10 (32.3)	8 (27.6)	74 (27.2)	66 (27.2)
	65-74	28 (37.3)	22 (45.8)	29 (42.0)	39 (41.1)	10 (32.3)	8 (27.6)	108 (39.7)	100 (41.2)
	>=75	16 (21.3)	15 (31.3)	22 (31.9)	29 (30.5)	11 (35.5)	13 (44.8)	90 (33.1)	77 (31.7)
Time since AF Diagnosis (Weeks)	n (missing)	75 (0)	38 (10)	52 (17)	66 (29)	23 (8)	23 (6)	202 (70)	179 (64)
	Mean (SD)	54.95 (22.71)	2.19 (1.93)	2.43 (1.94)	2.71 (1.86)	2.37 (2.10)	2.77 (2.04)	2.51 (1.94)	2.47 (1.92)
	Median (IQR)	49.20 (37.10 to 73.50)	1.30 (0.70 to 3.50)	2.05 (0.75 to 3.95)	2.40 (1.10 to 4.10)	1.40 (0.80 to 4.40)	2.20 (0.80 to 5.10)	2.05 (0.80 to 4.10)	2.00 (0.80 to 4.00)
	Min to Max	26.2 to 104.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	Caucasian	74 (98.7)	48 (100.0)	69 (100.0)	94 (98.9)	30 (96.8)	29 (100.0)	270 (99.3)	241 (99.2)
	Hispanic/Latino	1 (1.3)	-	-	-	-	-	-	-
	Asian (Not Chinese)	-	-	-	1 (1.1)	1 (3.2)	-	2 (0.7)	2 (0.8)

**Table 03 : Demographic Characteristics
Full Analysis Dataset : NORWAY**

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Region, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	Europe	75 (100.0)	48 (100.0)	69 (100.0)	95 (100.0)	31 (100.0)	29 (100.0)	272 (100.0)	243 (100.0)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : NORWAY**

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	Internal Medicine	6 (8.0)	4 (8.3)	6 (8.7)	13 (13.7)	6 (19.4)	7 (24.1)	36 (13.2)	29 (11.9)
	Cardiology	40 (53.3)	31 (64.6)	39 (56.5)	61 (64.2)	15 (48.4)	15 (51.7)	161 (59.2)	146 (60.1)
	Neurology	-	-	1 (1.4)	-	-	-	1 (0.4)	1 (0.4)
	Geriatrics	1 (1.3)	-	-	-	-	-	-	-
	Primary Care/General Practice	28 (37.3)	13 (27.1)	23 (33.3)	21 (22.1)	10 (32.3)	7 (24.1)	74 (27.2)	67 (27.6)
Care Setting Location at Diagnosis, n(%)	n (missing)	74 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	Hospital	21 (28.4)	14 (29.2)	24 (34.8)	23 (24.2)	13 (41.9)	11 (37.9)	85 (31.3)	74 (30.5)
	Office	50 (67.6)	32 (66.7)	42 (60.9)	67 (70.5)	18 (58.1)	16 (55.2)	175 (64.3)	159 (65.4)
	Anticoagulation clinic/thrombosis centre	1 (1.4)	-	-	-	-	-	-	-
	Emergency room	2 (2.7)	2 (4.2)	3 (4.3)	5 (5.3)	-	2 (6.9)	12 (4.4)	10 (4.1)
	Unknown	1	-	-	-	-	-	-	-
Type of AF Diagnosed, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	Permanent	26 (34.7)	5 (10.4)	8 (11.6)	12 (12.6)	1 (3.2)	4 (13.8)	30 (11.0)	26 (10.7)
	Persistent	23 (30.7)	4 (8.3)	6 (8.7)	18 (18.9)	6 (19.4)	4 (13.8)	38 (14.0)	34 (14.0)
	Paroxysmal	25 (33.3)	14 (29.2)	20 (29.0)	34 (35.8)	15 (48.4)	13 (44.8)	96 (35.3)	83 (34.2)
	New	1 (1.3)	25 (52.1)	35 (50.7)	31 (32.6)	9 (29.0)	8 (27.6)	108 (39.7)	100 (41.2)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : NORWAY**

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Treatment Costs, n(%)	n (missing)	-	-	36 (1)	95 (0)	31 (0)	29 (0)	191 (1)	162 (1)
	Public insurance	-	-	36 (100.0)	91 (95.8)	26 (83.9)	29 (100.0)	182 (95.3)	153 (94.4)
	Combination	-	-	-	4 (4.2)	5 (16.1)	-	9 (4.7)	9 (5.6)
	Unknown	75	48	32	-	-	-	80	80
Treatment Sector, n(%)	n (missing)	-	-	36 (1)	95 (0)	31 (0)	29 (0)	191 (1)	162 (1)
	In the public sector	-	-	33 (91.7)	93 (97.9)	31 (100.0)	29 (100.0)	186 (97.4)	157 (96.9)
	In the private sector	-	-	3 (8.3)	2 (2.1)	-	-	5 (2.6)	5 (3.1)
	Unknown	75	48	32	-	-	-	80	80

**Table 05 : Vital signs and life style
Full Analysis Dataset : NORWAY**

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Height (cm)	n (missing)	54 (21)	45 (3)	45 (24)	68 (27)	19 (12)	18 (11)	195 (77)	177 (66)
	Mean (SD)	176.2 (8.9)	173.9 (9.4)	174.7 (10.3)	175.0 (10.2)	172.9 (10.0)	173.4 (8.3)	174.3 (9.8)	174.4 (9.9)
	Median (IQR)	179.0 (169.0 to 183.0)	173.0 (167.0 to 180.0)	176.0 (168.0 to 183.0)	175.0 (168.5 to 181.0)	172.0 (163.0 to 183.0)	173.5 (168.0 to 180.0)	174.0 (168.0 to 181.0)	174.0 (168.0 to 181.0)
	Min to Max	158 to 195	156 to 193	150 to 191	153 to 195	160 to 190	155 to 186	150 to 195	150 to 195
Weight (kg)	n (missing)	54 (21)	45 (3)	45 (24)	68 (27)	19 (12)	18 (11)	195 (77)	177 (66)
	Mean (SD)	84.4 (16.3)	83.9 (18.7)	88.3 (20.4)	87.7 (18.2)	86.6 (20.3)	86.3 (23.1)	86.7 (19.4)	86.8 (19.0)
	Median (IQR)	82.5 (72.0 to 96.0)	82.0 (72.0 to 95.0)	89.0 (76.0 to 98.0)	88.0 (77.0 to 98.5)	82.0 (71.0 to 97.0)	82.5 (70.0 to 102.0)	85.0 (75.0 to 97.0)	85.0 (75.0 to 97.0)
	Min to Max	59 to 145	51 to 145	41 to 150	51 to 133	64 to 137	49 to 136	41 to 150	41 to 150
BMI (kg/m ²)	n (missing)	54 (21)	45 (3)	45 (24)	68 (27)	19 (12)	18 (11)	195 (77)	177 (66)
	Mean (SD)	27.1 (4.0)	27.7 (4.6)	29.0 (6.8)	28.6 (5.3)	28.9 (5.6)	28.8 (8.1)	28.5 (5.8)	28.5 (5.6)
	Median (IQR)	27.0 (24.0 to 29.0)	27.0 (24.0 to 30.0)	28.0 (26.0 to 32.0)	28.5 (25.0 to 32.0)	27.0 (26.0 to 32.0)	28.0 (22.0 to 31.0)	28.0 (25.0 to 31.0)	28.0 (25.0 to 31.0)
	Min to Max	20 to 41	19 to 42	15 to 51	19 to 46	24 to 46	18 to 46	15 to 51	15 to 51
BMI Category, n(%)	n (missing)	54 (21)	45 (3)	45 (24)	68 (27)	19 (12)	18 (11)	195 (77)	177 (66)
	<19	-	1 (2.2)	2 (4.4)	-	-	1 (5.6)	4 (2.1)	3 (1.7)
	19-<25	16 (29.6)	15 (33.3)	9 (20.0)	16 (23.5)	3 (15.8)	6 (33.3)	49 (25.1)	43 (24.3)
	25-<30	31 (57.4)	18 (40.0)	17 (37.8)	27 (39.7)	11 (57.9)	6 (33.3)	79 (40.5)	73 (41.2)
	30-<40	6 (11.1)	10 (22.2)	15 (33.3)	24 (35.3)	4 (21.1)	2 (11.1)	55 (28.2)	53 (29.9)
	>=40	1 (1.9)	1 (2.2)	2 (4.4)	1 (1.5)	1 (5.3)	3 (16.7)	8 (4.1)	5 (2.8)
Pulse (bpm)	n (missing)	57 (18)	43 (5)	58 (11)	89 (6)	27 (4)	27 (2)	244 (28)	217 (26)
	Mean (SD)	86.3 (25.7)	99.9 (28.6)	98.1 (27.7)	95.7 (28.4)	82.8 (25.3)	89.2 (25.7)	94.9 (27.9)	95.6 (28.2)
	Median (IQR)	81.0 (69.0 to 96.0)	96.0 (75.0 to 127.0)	96.0 (72.0 to 120.0)	90.0 (73.0 to 112.0)	77.0 (61.0 to 98.0)	85.0 (69.0 to 115.0)	90.0 (71.0 to 115.0)	90.0 (72.0 to 115.0)
	Min to Max	34 to 158	57 to 170	55 to 170	52 to 160	50 to 146	50 to 146	50 to 170	50 to 170

**Table 05 : Vital signs and life style
Full Analysis Dataset : NORWAY**

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Systolic BP (mm Hg)	n (missing)	62 (13)	42 (6)	62 (7)	87 (8)	26 (5)	25 (4)	242 (30)	217 (26)
	Mean (SD)	133.9 (17.5)	137.1 (21.2)	136.4 (19.8)	139.8 (21.2)	140.5 (19.7)	132.5 (20.9)	137.8 (20.6)	138.4 (20.5)
	Median (IQR)	130.5 (122.0 to 145.0)	140.0 (118.0 to 150.0)	138.0 (120.0 to 148.0)	140.0 (125.0 to 153.0)	139.0 (125.0 to 150.0)	130.0 (123.0 to 144.0)	140.0 (121.0 to 150.0)	140.0 (121.0 to 150.0)
	Min to Max	100 to 180	96 to 182	103 to 199	98 to 210	97 to 176	88 to 172	88 to 210	96 to 210
Diastolic BP (mm Hg)	n (missing)	62 (13)	42 (6)	62 (7)	87 (8)	26 (5)	25 (4)	242 (30)	217 (26)
	Mean (SD)	81.8 (11.4)	85.7 (17.4)	82.7 (12.5)	85.4 (14.2)	83.5 (13.4)	83.0 (15.4)	84.3 (14.4)	84.5 (14.3)
	Median (IQR)	80.0 (72.0 to 90.0)	87.0 (70.0 to 92.0)	80.5 (73.0 to 90.0)	84.0 (76.0 to 94.0)	82.5 (71.0 to 90.0)	82.0 (70.0 to 95.0)	83.5 (74.0 to 92.0)	84.0 (75.0 to 91.0)
	Min to Max	56 to 110	53 to 132	52 to 113	50 to 139	64 to 111	58 to 110	50 to 139	50 to 139
LVEF (%)	n (missing)	36 (39)	21 (27)	30 (39)	53 (42)	12 (19)	10 (19)	126 (146)	116 (127)
	Mean (SD)	53.1 (12.4)	54.7 (11.0)	52.3 (12.1)	51.7 (11.1)	51.4 (13.4)	54.3 (4.0)	52.5 (11.1)	52.3 (11.5)
	Median (IQR)	50.0 (45.0 to 63.0)	57.0 (50.0 to 60.0)	52.5 (50.0 to 60.0)	53.0 (45.0 to 58.0)	57.5 (42.5 to 60.0)	54.5 (51.0 to 57.0)	54.0 (50.0 to 60.0)	54.0 (49.5 to 60.0)
	Min to Max	30 to 75	30 to 70	21 to 79	30 to 75	27 to 67	48 to 60	21 to 79	21 to 79
LVEF Category, n (missing) n(%)	n (missing)	36 (39)	21 (27)	30 (39)	53 (42)	12 (19)	10 (19)	126 (146)	116 (127)
	<40%	6 (16.7)	2 (9.5)	3 (10.0)	9 (17.0)	3 (25.0)	-	17 (13.5)	17 (14.7)
	>=40%	30 (83.3)	19 (90.5)	27 (90.0)	44 (83.0)	9 (75.0)	10 (100.0)	109 (86.5)	99 (85.3)
History of Hypertension, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	16 (21.3)	17 (35.4)	23 (33.3)	22 (23.2)	7 (22.6)	14 (48.3)	83 (30.5)	69 (28.4)
	Yes	59 (78.7)	31 (64.6)	46 (66.7)	73 (76.8)	24 (77.4)	15 (51.7)	189 (69.5)	174 (71.6)

**Table 05 : Vital signs and life style
Full Analysis Dataset : NORWAY**

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Alcohol Consumption, n(%)	n (missing)	49 (0)	37 (0)	49 (0)	73 (0)	23 (0)	22 (0)	204 (0)	182 (0)
	Abstinent	6 (12.2)	5 (13.5)	5 (10.2)	6 (8.2)	3 (13.0)	2 (9.1)	21 (10.3)	19 (10.4)
	Light	33 (67.3)	27 (73.0)	26 (53.1)	47 (64.4)	12 (52.2)	9 (40.9)	121 (59.3)	112 (61.5)
	Moderate	8 (16.3)	3 (8.1)	17 (34.7)	19 (26.0)	8 (34.8)	11 (50.0)	58 (28.4)	47 (25.8)
	Heavy	2 (4.1)	2 (5.4)	1 (2.0)	1 (1.4)	-	-	4 (2.0)	4 (2.2)
	Unknown	26	11	20	22	8	7	68	61
Smoker, n(%)	n (missing)	67 (0)	46 (0)	58 (0)	89 (0)	28 (0)	26 (0)	247 (0)	221 (0)
	No	31 (46.3)	25 (54.3)	30 (51.7)	42 (47.2)	16 (57.1)	14 (53.8)	127 (51.4)	113 (51.1)
	Ex-smoker	26 (38.8)	16 (34.8)	21 (36.2)	36 (40.4)	9 (32.1)	7 (26.9)	89 (36.0)	82 (37.1)
	Current smoker	10 (14.9)	5 (10.9)	7 (12.1)	11 (12.4)	3 (10.7)	5 (19.2)	31 (12.6)	26 (11.8)
	Unknown	8	2	11	6	3	3	25	22

Table 06 : Clinical History
Full Analysis Dataset : NORWAY

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Congestive heart failure, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	69 (92.0)	44 (91.7)	63 (91.3)	85 (89.5)	29 (93.5)	28 (96.6)	249 (91.5)	221 (90.9)
	Yes	6 (8.0)	4 (8.3)	6 (8.7)	10 (10.5)	2 (6.5)	1 (3.4)	23 (8.5)	22 (9.1)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	6 (69)	4 (44)	3 (63)	7 (85)	2 (29)	1 (28)	17 (249)	16 (221)
	I	1 (16.7)	1 (25.0)	1 (33.3)	2 (28.6)	-	-	4 (23.5)	4 (25.0)
	II	3 (50.0)	1 (25.0)	1 (33.3)	3 (42.9)	2 (100.0)	1 (100.0)	8 (47.1)	7 (43.8)
	III	2 (33.3)	2 (50.0)	1 (33.3)	2 (28.6)	-	-	5 (29.4)	5 (31.3)
	Unknown	-	-	3	3	-	-	6	6
Coronary artery disease, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	56 (74.7)	44 (91.7)	61 (88.4)	80 (84.2)	24 (77.4)	26 (89.7)	235 (86.4)	209 (86.0)
	Yes	19 (25.3)	4 (8.3)	8 (11.6)	15 (15.8)	7 (22.6)	3 (10.3)	37 (13.6)	34 (14.0)
Acute coronary syndrome, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	94 (0)	31 (0)	29 (0)	271 (0)	242 (0)
	No	65 (86.7)	45 (93.8)	65 (94.2)	86 (91.5)	27 (87.1)	28 (96.6)	251 (92.6)	223 (92.1)
	Yes	10 (13.3)	3 (6.3)	4 (5.8)	8 (8.5)	4 (12.9)	1 (3.4)	20 (7.4)	19 (7.9)
	Unknown	-	-	-	1	-	-	1	1
Carotid Occlusive Disease, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	94 (0)	31 (0)	29 (0)	271 (0)	242 (0)
	No	73 (97.3)	48 (100.0)	68 (98.6)	90 (95.7)	30 (96.8)	27 (93.1)	263 (97.0)	236 (97.5)
	Yes	2 (2.7)	-	1 (1.4)	4 (4.3)	1 (3.2)	2 (6.9)	8 (3.0)	6 (2.5)

Table 06 : Clinical History
Full Analysis Dataset : NORWAY

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
	Unknown	-	-	-	1	-	-	1	1
PE or DVT, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	75 (100.0)	48 (100.0)	67 (97.1)	95 (100.0)	31 (100.0)	28 (96.6)	269 (98.9)	241 (99.2)
	Yes	-	-	2 (2.9)	-	-	1 (3.4)	3 (1.1)	2 (0.8)
Other Thromboemboli sm, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	0 (95)	0 (31)	0 (29)	117 (155)	117 (126)
	No	74 (98.7)	48 (100.0)	69 (100.0)	-	-	-	117 (100.0)	117 (100.0)
	Yes	1 (1.3)	-	-	-	-	-	-	-
Systemic Embolization, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	73 (97.3)	48 (100.0)	69 (100.0)	94 (98.9)	31 (100.0)	29 (100.0)	271 (99.6)	242 (99.6)
	Yes	2 (2.7)	-	-	1 (1.1)	-	-	1 (0.4)	1 (0.4)
Coronary Artery Bypass Graft, n(%)	n (missing)	70 (0)	46 (0)	69 (0)	95 (0)	31 (0)	29 (0)	270 (0)	241 (0)
	No	67 (95.7)	45 (97.8)	68 (98.6)	94 (98.9)	27 (87.1)	27 (93.1)	261 (96.7)	234 (97.1)
	Yes	3 (4.3)	1 (2.2)	1 (1.4)	1 (1.1)	4 (12.9)	2 (6.9)	9 (3.3)	7 (2.9)
	Unknown	5	2	-	-	-	-	2	2
Stroke/TIA, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	66 (88.0)	43 (89.6)	63 (91.3)	89 (93.7)	29 (93.5)	24 (82.8)	248 (91.2)	224 (92.2)
	Yes	9 (12.0)	5 (10.4)	6 (8.7)	6 (6.3)	2 (6.5)	5 (17.2)	24 (8.8)	19 (7.8)

Table 06 : Clinical History
Full Analysis Dataset : NORWAY

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Stroke, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	68 (90.7)	46 (95.8)	65 (94.2)	95 (100.0)	29 (93.5)	26 (89.7)	261 (96.0)	235 (96.7)
	Yes	7 (9.3)	2 (4.2)	4 (5.8)	-	2 (6.5)	3 (10.3)	11 (4.0)	8 (3.3)
History of Bleeding, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	28 (0)	271 (0)	243 (0)
	No	71 (94.7)	48 (100.0)	68 (98.6)	93 (97.9)	31 (100.0)	27 (96.4)	267 (98.5)	240 (98.8)
	Yes	4 (5.3)	-	1 (1.4)	2 (2.1)	-	1 (3.6)	4 (1.5)	3 (1.2)
	Unknown	-	-	-	-	-	1	1	-
Hypercholester olaemia, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	94 (0)	31 (0)	29 (0)	271 (0)	242 (0)
	No	42 (56.0)	28 (58.3)	36 (52.2)	42 (44.7)	15 (48.4)	16 (55.2)	137 (50.6)	121 (50.0)
	Yes	33 (44.0)	20 (41.7)	33 (47.8)	52 (55.3)	16 (51.6)	13 (44.8)	134 (49.4)	121 (50.0)
	Unknown	-	-	-	1	-	-	1	1
Diabetes, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	65 (86.7)	43 (89.6)	60 (87.0)	81 (85.3)	28 (90.3)	26 (89.7)	238 (87.5)	212 (87.2)
	Type I	-	-	-	1 (1.1)	-	-	1 (0.4)	1 (0.4)
	Type II	10 (13.3)	5 (10.4)	9 (13.0)	13 (13.7)	3 (9.7)	3 (10.3)	33 (12.1)	30 (12.3)
Diabetes, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	65 (86.7)	43 (89.6)	60 (87.0)	81 (85.3)	28 (90.3)	26 (89.7)	238 (87.5)	212 (87.2)
	Yes	10 (13.3)	5 (10.4)	9 (13.0)	14 (14.7)	3 (9.7)	3 (10.3)	34 (12.5)	31 (12.8)
Cirrhosis, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	75 (100.0)	48 (100.0)	69 (100.0)	95 (100.0)	31 (100.0)	29 (100.0)	272 (100.0)	243 (100.0)
Dementia, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	74 (98.7)	48 (100.0)	69 (100.0)	95 (100.0)	31 (100.0)	29 (100.0)	272 (100.0)	243 (100.0)
	Yes	1 (1.3)	-	-	-	-	-	-	-

Table 06 : Clinical History
Full Analysis Dataset : NORWAY

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Hyperthyroidism, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	94 (0)	31 (0)	29 (0)	271 (0)	242 (0)
	No	75 (100.0)	48 (100.0)	69 (100.0)	92 (97.9)	30 (96.8)	29 (100.0)	268 (98.9)	239 (98.8)
	Yes	-	-	-	2 (2.1)	1 (3.2)	-	3 (1.1)	3 (1.2)
	Unknown	-	-	-	1	-	-	1	1
Hypothyroidism, n (missing) n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	75 (100.0)	43 (89.6)	63 (91.3)	91 (95.8)	27 (87.1)	26 (89.7)	250 (91.9)	224 (92.2)
	Yes	-	5 (10.4)	6 (8.7)	4 (4.2)	4 (12.9)	3 (10.3)	22 (8.1)	19 (7.8)
Vascular Disease, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	94 (1)	31 (0)	29 (0)	271 (1)	242 (1)
	No	58 (77.3)	44 (91.7)	59 (85.5)	83 (88.3)	26 (83.9)	26 (89.7)	238 (87.8)	212 (87.6)
	Yes	17 (22.7)	4 (8.3)	10 (14.5)	11 (11.7)	5 (16.1)	3 (10.3)	33 (12.2)	30 (12.4)
Moderate to Severe CKD, n(%)	n (missing)	75 (0)	48 (0)	69 (0)	95 (0)	31 (0)	29 (0)	272 (0)	243 (0)
	No	73 (97.3)	46 (95.8)	66 (95.7)	88 (92.6)	29 (93.5)	28 (96.6)	257 (94.5)	229 (94.2)
	Yes	2 (2.7)	2 (4.2)	3 (4.3)	7 (7.4)	2 (6.5)	1 (3.4)	15 (5.5)	14 (5.8)

**Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : NORWAY**

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Baseline Treatment, n(%)	n (missing)	75 (0)	47 (0)	69 (0)	95 (0)	30 (0)	28 (0)	269 (0)	241 (0)
	VKA	48 (64.0)	32 (68.1)	50 (72.5)	15 (15.8)	4 (13.3)	2 (7.1)	103 (38.3)	101 (41.9)
	VKA+AP	13 (17.3)	6 (12.8)	3 (4.3)	5 (5.3)	3 (10.0)	1 (3.6)	18 (6.7)	17 (7.1)
	FXA	-	-	-	27 (28.4)	11 (36.7)	14 (50.0)	52 (19.3)	38 (15.8)
	FXA+AP	-	1 (2.1)	-	2 (2.1)	2 (6.7)	3 (10.7)	8 (3.0)	5 (2.1)
	DTI	1 (1.3)	-	9 (13.0)	33 (34.7)	2 (6.7)	2 (7.1)	46 (17.1)	44 (18.3)
	DTI+AP	-	-	3 (4.3)	2 (2.1)	1 (3.3)	-	6 (2.2)	6 (2.5)
	AP	9 (12.0)	1 (2.1)	1 (1.4)	4 (4.2)	4 (13.3)	4 (14.3)	14 (5.2)	10 (4.1)
	NONE	4 (5.3)	7 (14.9)	3 (4.3)	7 (7.4)	3 (10.0)	2 (7.1)	22 (8.2)	20 (8.3)
	Unknown	-	1	-	-	1	1	3	2
	VKA±AP	61 (81.3)	38 (80.9)	53 (76.8)	20 (21.1)	7 (23.3)	3 (10.7)	121 (45.0)	118 (49.0)
	FXA±AP	-	1 (2.1)	-	29 (30.5)	13 (43.3)	17 (60.7)	60 (22.3)	43 (17.8)
	DTI±AP	1 (1.3)	-	12 (17.4)	35 (36.8)	3 (10.0)	2 (7.1)	52 (19.3)	50 (20.7)
	FXA/DTI	1 (1.3)	-	9 (13.0)	60 (63.2)	13 (43.3)	16 (57.1)	98 (36.4)	82 (34.0)
	FXA/DTI+AP	-	1 (2.1)	3 (4.3)	4 (4.2)	3 (10.0)	3 (10.7)	14 (5.2)	11 (4.6)
	FXA/DTI±AP	1 (1.3)	1 (2.1)	12 (17.4)	64 (67.4)	16 (53.3)	19 (67.9)	112 (41.6)	93 (38.6)
	AC	49 (65.3)	32 (68.1)	59 (85.5)	75 (78.9)	17 (56.7)	18 (64.3)	201 (74.7)	183 (75.9)
	AC+AP	13 (17.3)	7 (14.9)	6 (8.7)	9 (9.5)	6 (20.0)	4 (14.3)	32 (11.9)	28 (11.6)
	AC±AP	62 (82.7)	39 (83.0)	65 (94.2)	84 (88.4)	23 (76.7)	22 (78.6)	233 (86.6)	211 (87.6)

Table 08: Treatment
Full Analysis Dataset : NORWAY

	Cohort 1 Retrospective (N=75) (n %)	Cohort 1 Prospective (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
Anti-platelet (non mutually exclusive groups)								
Glycoprotein inhibitors	-	-	-	1 (1.1)	-	-	1 (0.4)	1 (0.4)
ADP receptor/P2Y12 inhibitors	3 (4.0)	1 (2.1)	1 (1.4)	1 (1.1)	-	-	3 (1.1)	3 (1.2)
Cox inhibitors	-	1 (2.1)	-	-	1 (3.2)	-	2 (0.7)	2 (0.8)
ASA	16 (21.3)	8 (16.7)	7 (10.1)	12 (12.6)	9 (29.0)	8 (27.6)	44 (16.2)	36 (14.8)
Anticoagulant drugs (non mutually exclusive groups)								
VKA	61 (81.3)	39 (81.3)	53 (76.8)	20 (21.1)	7 (22.6)	3 (10.3)	122 (44.9)	119 (49.0)
FXa	-	2 (4.2)	-	29 (30.5)	14 (45.2)	18 (62.1)	63 (23.2)	45 (18.5)
DTI	1 (1.3)	-	12 (17.4)	35 (36.8)	4 (12.9)	3 (10.3)	54 (19.9)	51 (21.0)
Heparinoid	1 (1.3)	-	1 (1.4)	-	-	-	1 (0.4)	1 (0.4)
Heparins	4 (5.3)	-	1 (1.4)	-	-	-	1 (0.4)	1 (0.4)
Other	-	-	-	1 (1.1)	-	-	1 (0.4)	1 (0.4)

Table 09 : Risk scores
Full Analysis Dataset : NORWAY

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
CHADS2 Score	n (missing)	72 (3)	46 (2)	66 (3)	95 (0)	30 (1)	26 (3)	263 (9)	237 (6)
	Mean (SD)	1.5 (1.0)	1.5 (1.0)	1.5 (0.8)	1.6 (0.9)	1.5 (0.8)	1.7 (1.2)	1.5 (0.9)	1.5 (0.9)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 5	0 to 5	0 to 4	0 to 4	0 to 4	0 to 5	0 to 5	0 to 5
CHADS2 score categories, n(%)	n (missing)	72 (3)	46 (2)	66 (3)	95 (0)	30 (1)	26 (3)	263 (9)	237 (6)
	0	7 (9.7)	5 (10.9)	4 (6.1)	7 (7.4)	2 (6.7)	4 (15.4)	22 (8.4)	18 (7.6)
	1	34 (47.2)	21 (45.7)	35 (53.0)	44 (46.3)	13 (43.3)	9 (34.6)	122 (46.4)	113 (47.7)
	2	23 (31.9)	17 (37.0)	19 (28.8)	31 (32.6)	13 (43.3)	8 (30.8)	88 (33.5)	80 (33.8)
	3	3 (4.2)	-	7 (10.6)	10 (10.5)	1 (3.3)	3 (11.5)	21 (8.0)	18 (7.6)
	4	4 (5.6)	2 (4.3)	1 (1.5)	3 (3.2)	1 (3.3)	1 (3.8)	8 (3.0)	7 (3.0)
	5	1 (1.4)	1 (2.2)	-	-	-	1 (3.8)	2 (0.8)	1 (0.4)
CHA2DS2- VASc Score	n (missing)	72 (3)	46 (2)	66 (3)	94 (1)	30 (1)	26 (3)	262 (10)	236 (7)
	Mean (SD)	2.7 (1.5)	2.8 (1.5)	2.7 (1.2)	2.8 (1.3)	2.8 (1.3)	2.9 (1.7)	2.8 (1.3)	2.8 (1.3)
	Median (IQR)	2.5 (1.0 to 4.0)	2.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 7	1 to 7	0 to 6	1 to 6	1 to 5	0 to 7	0 to 7	0 to 7
CHA2DS2- VASc score categories, n(%)	n (missing)	72 (3)	46 (2)	66 (3)	94 (1)	30 (1)	26 (3)	262 (10)	236 (7)
	0	1 (1.4)	-	2 (3.0)	-	-	2 (7.7)	4 (1.5)	2 (0.8)
	1	18 (25.0)	9 (19.6)	7 (10.6)	15 (16.0)	7 (23.3)	3 (11.5)	41 (15.6)	38 (16.1)
	2	17 (23.6)	15 (32.6)	20 (30.3)	25 (26.6)	5 (16.7)	5 (19.2)	70 (26.7)	65 (27.5)
	3	17 (23.6)	8 (17.4)	20 (30.3)	26 (27.7)	9 (30.0)	7 (26.9)	70 (26.7)	63 (26.7)
	4	8 (11.1)	10 (21.7)	13 (19.7)	19 (20.2)	6 (20.0)	6 (23.1)	54 (20.6)	48 (20.3)
	5	8 (11.1)	1 (2.2)	3 (4.5)	7 (7.4)	3 (10.0)	1 (3.8)	15 (5.7)	14 (5.9)

Table 09 : Risk scores
Full Analysis Dataset : NORWAY

Variable	Statistics	Cohort 1 Retrospective patients (N=75) (n %)	Cohort 1 Prospective patients (N=48) (n %)	Cohort 2 (N=69) (n %)	Cohort 3 (N=95) (n %)	Cohort 4 (N=31) (n %)	Cohort 5 (N=29) (n %)	Total Prospective patients Cohorts 1 to 5 (N=272)	Total Prospective patients Cohorts 1 to 4 (N=243)
	6-9	3 (4.2)	3 (6.5)	1 (1.5)	2 (2.1)	-	2 (7.7)	8 (3.1)	6 (2.5)
HAS-BLED score	n (missing)	30 (45)	32 (16)	39 (30)	67 (28)	19 (12)	19 (10)	176 (96)	157 (86)
	Mean (SD)	1.2 (0.8)	1.3 (0.7)	1.2 (0.7)	1.1 (0.9)	1.3 (0.9)	1.2 (0.9)	1.2 (0.8)	1.2 (0.8)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (0.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 3	0 to 2	0 to 2	0 to 4	0 to 3	0 to 3	0 to 4	0 to 4
HAS-BLED score categories, n(%)	n (missing)	30 (45)	32 (16)	39 (30)	67 (28)	19 (12)	19 (10)	176 (96)	157 (86)
	0	7 (23.3)	4 (12.5)	8 (20.5)	16 (23.9)	3 (15.8)	5 (26.3)	36 (20.5)	31 (19.7)
	1	12 (40.0)	16 (50.0)	17 (43.6)	30 (44.8)	10 (52.6)	7 (36.8)	80 (45.5)	73 (46.5)
	2	10 (33.3)	12 (37.5)	14 (35.9)	18 (26.9)	3 (15.8)	6 (31.6)	53 (30.1)	47 (29.9)
	3	1 (3.3)	-	-	2 (3.0)	3 (15.8)	1 (5.3)	6 (3.4)	5 (3.2)
	4	-	-	-	1 (1.5)	-	-	1 (0.6)	1 (0.6)

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : NORWAY**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 1 retrospective	0	1	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1	12	66.7	2	11.1	-	-	-	-	-	-	-	-	3	16.7	1	5.6	-	-
	2	11	64.7	3	17.6	-	-	-	-	1	5.9	-	-	-	-	2	11.8	-	-
	3	15	88.2	1	5.9	-	-	-	-	-	-	-	-	1	5.9	-	-	-	-
	4	4	50	1	12.5	-	-	-	-	-	-	-	-	2	25	1	12.5	-	-
	5	3	37.5	3	37.5	-	-	-	-	-	-	-	-	2	25	-	-	-	-
	6-9	1	33.3	2	66.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cohort 1 prospective	1	5	55.6	1	11.1	-	-	-	-	-	-	-	-	-	-	3	33.3	-	-
	2	12	80	1	6.7	-	-	-	-	-	-	-	-	-	-	2	13.3	-	-
	3	5	62.5	2	25	-	-	-	-	-	-	-	-	-	-	1	12.5	-	-
	4	8	80	1	10	-	-	-	-	-	-	-	-	-	-	1	10	-	-
	5	-	-	-	-	-	-	1	100	-	-	-	-	-	-	-	-	-	-
	6-9	1	50	-	-	-	-	-	-	-	-	-	-	1	50	-	-	-	1
Cohort 2	0	2	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1	3	42.9	-	-	-	-	-	-	2	28.6	-	-	-	-	2	28.6	-	-
	2	13	65	2	10	-	-	-	-	4	20	-	-	1	5	-	-	-	-
	3	16	80	1	5	-	-	-	-	1	5	2	10	-	-	-	-	-	-
	4	9	69.2	-	-	-	-	-	-	2	15.4	1	7.7	-	-	1	7.7	-	-
	5	3	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	6-9	1	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cohort 3	1	1	6.7	-	-	-	-	1	6.7	8	53.3	1	6.7	1	6.7	3	20	-	-
	2	6	24	-	-	4	16	-	-	11	44	-	-	-	-	4	16	-	-
	3	4	15.4	2	7.7	9	34.6	-	-	9	34.6	1	3.8	1	3.8	-	-	-	-
	4	1	5.3	3	15.8	9	47.4	1	5.3	4	21.1	-	-	1	5.3	-	-	-	-
	5	3	42.9	-	-	4	57.1	-	-	-	-	-	-	-	-	-	-	-	-
	6-9	-	-	-	-	1	50	-	-	1	50	-	-	-	-	-	-	-	-

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : NORWAY**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 4	1	-	-	1	14.3	2	28.6	-	-	1	14.3	-	-	1	14.3	2	28.6	-	-
	2	1	25	-	-	1	25	-	-	1	25	1	25	-	-	-	-	-	1
	3	1	11.1	1	11.1	3	33.3	1	11.1	-	-	-	-	3	33.3	-	-	-	-
	4	1	16.7	1	16.7	4	66.7	-	-	-	-	-	-	-	-	-	-	-	-
	5	1	33.3	-	-	1	33.3	1	33.3	-	-	-	-	-	-	-	-	-	-
Cohort 5	0	-	-	-	-	1	50	-	-	1	50	-	-	-	-	-	-	-	-
	1	-	-	-	-	1	33.3	-	-	-	-	-	-	-	-	2	66.7	-	-
	2	-	-	-	-	4	80	-	-	-	-	-	-	1	20	-	-	-	-
	3	1	14.3	-	-	3	42.9	-	-	1	14.3	-	-	2	28.6	-	-	-	-
	4	-	-	1	20	3	60	1	20	-	-	-	-	-	-	-	-	-	1
	5	-	-	-	-	-	-	1	100	-	-	-	-	-	-	-	-	-	-
Total Prospective patients Cohorts 1 to 5	0	2	50	-	-	1	25	-	-	1	25	-	-	-	-	-	-	-	-
	1	9	22	2	4.9	3	7.3	1	2.4	11	26.8	1	2.4	2	4.9	12	29.3	-	-
	2	32	46.4	3	4.3	9	13	-	-	16	23.2	1	1.4	2	2.9	6	8.7	1	-
	3	27	38.6	6	8.6	15	21.4	1	1.4	11	15.7	3	4.3	6	8.6	1	1.4	-	-
	4	19	35.8	6	11.3	16	30.2	2	3.8	6	11.3	1	1.9	1	1.9	2	3.8	1	-
	5	7	46.7	-	-	5	33.3	3	20	-	-	-	-	-	-	-	-	-	-
	6-9	3	42.9	-	-	1	14.3	1	14.3	1	14.3	-	-	1	14.3	-	-	-	1

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : NORWAY**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Total	0	2	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prospective patients Cohorts 1 to 4																			
	1	9	23.7	2	5.3	2	5.3	1	2.6	11	28.9	1	2.6	2	5.3	10	26.3	-	
	2	32	50	3	4.7	5	7.8	-	-	16	25	1	1.6	1	1.6	6	9.4	1	
	3	26	41.3	6	9.5	12	19	1	1.6	10	15.9	3	4.8	4	6.3	1	1.6	-	
	4	19	39.6	5	10.4	13	27.1	1	2.1	6	12.5	1	2.1	1	2.1	2	4.2	-	
	5	7	50	-	-	5	35.7	2	14.3	-	-	-	-	-	-	-	-	-	
	6-9	2	40	-	-	1	20	-	-	1	20	-	-	1	20	-	-	1	

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : NORWAY**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 1 retrospective	0	7	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1	11	91.7	-	-	-	-	-	-	-	-	-	-	-	-	-	1	8.3	-
	2	6	60	1	10	-	-	-	-	-	-	-	-	3	30	-	-	-	-
	3	-	-	1	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cohort 1 prospective	0	1	25	-	-	-	-	-	-	-	-	-	-	-	-	3	75	-	-
	1	15	93.8	-	-	-	-	-	-	-	-	-	-	-	-	1	6.3	-	-
	2	8	72.7	2	18.2	-	-	1	9.1	-	-	-	-	-	-	-	-	-	1
Cohort 2	0	4	50	-	-	-	-	-	-	2	25	-	-	-	-	2	25	-	-
	1	17	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	2	6	42.9	2	14.3	-	-	-	-	3	21.4	2	14.3	1	7.1	-	-	-	-
Cohort 3	0	2	12.5	-	-	1	6.3	-	-	10	62.5	-	-	-	-	3	18.8	-	-
	1	6	20	-	-	16	53.3	2	6.7	4	13.3	1	3.3	-	-	1	3.3	-	-
	2	3	16.7	4	22.2	4	22.2	-	-	5	27.8	1	5.6	1	5.6	-	-	-	-
	3	-	-	-	-	-	-	-	-	-	-	-	-	1	50	1	50	-	-
	4-9	-	-	-	-	-	-	-	-	1	100	-	-	-	-	-	-	-	-
Cohort 4	0	-	-	-	-	-	-	-	-	1	50	-	-	-	-	1	50	1	-
	1	1	10	-	-	6	60	-	-	1	10	1	10	1	10	-	-	-	-
	2	1	33.3	-	-	1	33.3	1	33.3	-	-	-	-	-	-	-	-	-	-
	3	1	33.3	-	-	-	-	1	33.3	-	-	-	-	1	33.3	-	-	-	-
Cohort 5	0	-	-	-	-	3	60	-	-	1	20	-	-	-	-	1	20	-	-
	1	1	14.3	-	-	5	71.4	-	-	1	14.3	-	-	-	-	-	-	-	-
	2	1	16.7	-	-	3	50	1	16.7	-	-	-	-	1	16.7	-	-	-	-
	3	-	-	-	-	-	-	-	-	-	-	-	-	1	100	-	-	-	-

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : NORWAY**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total	0	7	20	-	-	4	11.4	-	-	14	40	-	-	-	-	10	28.6	1
Prospective patients Cohorts 1 to 5																		
	1	40	50	-	-	27	33.8	2	2.5	6	7.5	2	2.5	1	1.3	2	2.5	-
	2	19	36.5	8	15.4	8	15.4	3	5.8	8	15.4	3	5.8	3	5.8	-	-	1
	3	1	16.7	-	-	-	-	1	16.7	-	-	-	-	3	50	1	16.7	-
	4-9	-	-	-	-	-	-	-	-	1	100	-	-	-	-	-	-	-
Total	0	7	23.3	-	-	1	3.3	-	-	13	43.3	-	-	-	-	9	30	1
Prospective patients Cohorts 1 to 4																		
	1	39	53.4	-	-	22	30.1	2	2.7	5	6.8	2	2.7	1	1.4	2	2.7	-
	2	18	39.1	8	17.4	5	10.9	2	4.3	8	17.4	3	6.5	2	4.3	-	-	1
	3	1	20	-	-	-	-	1	20	-	-	-	-	2	40	1	20	-
	4-9	-	-	-	-	-	-	-	-	1	100	-	-	-	-	-	-	-

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : NORWAY**

Variable	Statistics	Cohort 1 Prospective patients (N=38) (n %)	Cohort 2 (N=53) (n %)	Cohort 3 (N=20) (n %)	Cohort 4 (N=7) (n %)	Total Prospective patients Cohorts 1 to 4 (N=118)
TTR value, n(%)	n (missing)	11 (27)	36 (17)	8 (12)	3 (4)	58 (60)
	<65	4 (36.4)	12 (33.3)	3 (37.5)	2 (66.7)	21 (36.2)
	>=65	7 (63.6)	24 (66.7)	5 (62.5)	1 (33.3)	37 (63.8)
TTR	n (missing)	11 (27)	36 (17)	8 (12)	3 (4)	58 (60)
	Mean (SD)	70.8 (23.2)	70.2 (24.1)	65.3 (26.8)	63.5 (12.9)	69.3 (23.5)
	Median (IQR)	78.6 (51.0 to 90.6)	75.7 (59.0 to 87.3)	72.8 (42.4 to 84.0)	60.3 (52.4 to 77.6)	75.3 (55.4 to 85.8)
	Min to Max	24.6 to 100.0	0.0 to 100.0	24.4 to 100.0	52.4 to 77.6	0.0 to 100.0
INR value, n(%)	n (missing)	183 (23)	471 (16)	92 (12)	39 (4)	785 (55)
	2-3	107 (58.5)	287 (60.9)	66 (71.7)	24 (61.5)	484 (61.7)
	<2	42 (23.0)	98 (20.8)	15 (16.3)	10 (25.6)	165 (21.0)
	>3	34 (18.6)	86 (18.3)	11 (12.0)	5 (12.8)	136 (17.3)
INR	n (missing)	183 (23)	471 (16)	92 (12)	39 (4)	785 (55)
	Mean (SD)	2.6 (1.0)	2.5 (0.9)	2.4 (0.7)	2.3 (0.7)	2.5 (0.9)
	Median (IQR)	2.4 (2.0 to 2.9)	2.5 (2.0 to 2.9)	2.3 (2.1 to 2.6)	2.2 (1.9 to 2.6)	2.4 (2.0 to 2.8)
	Min to Max	1.1 to 8.0	1.0 to 8.0	1.3 to 5.9	1.1 to 4.5	1.0 to 8.0

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : NORWAY**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		243	2	0.84	(0.21 to 3.37)
	Non-Cardiovascular death	243	1	0.42	(0.06 to 2.99)
	Undetermined cause	243	1	0.42	(0.06 to 2.99)
Stroke/SE		243	4	1.70	(0.64 to 4.52)
Major bleed		243	6	2.56	(1.15 to 5.70)
Acute coronary syndrome		243	2	0.85	(0.21 to 3.39)
Congestive Heart Failure		243	7	3.02	(1.44 to 6.33)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : NORWAY**

		NORWAY		
Outcome	Cause	N	Events	%
Non-cardiovascular causes	Malignancy	1	1	100.00

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :NORWAY**

OUTCOME	NORWAY		
	N	Events	%
Stroke(not including systemic embolism)	243	2	0.82
Primary Ischemic Stroke	243	2	0.82

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : NORWAY**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	2	2.00	0	-	-
1	38	35.97	0	-	-
2	65	63.92	1	1.57	(0.22 to 11.11)
3	63	61.10	0	-	-
4+	68	67.44	1	1.48	(0.21 to 10.53)
Unknown	7	7.00	0	-	-

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : NORWAY**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	2	2.00	0	-	-
1	38	35.70	1	2.80	(0.40 to 19.89)
2	65	63.68	1	1.57	(0.22 to 11.15)
3	63	60.65	1	1.65	(0.23 to 11.71)
4+	68	66.66	1	1.50	(0.21 to 10.65)
Unknown	7	7.00	0	-	-

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : NORWAY**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	2	2.00	0	-	-
1	38	35.90	1	2.79	(0.39 to 19.78)
2	65	63.84	1	1.57	(0.22 to 11.12)
3	63	60.32	1	1.66	(0.23 to 11.77)
4+	68	65.45	3	4.58	(1.48 to 14.21)
Unknown	7	7.00	0	-	-